New Zealand markets closed

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.11000.0000 (0.00%)
At close: 04:00PM EDT
2.1100 0.00 (0.00%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1100
Open2.1600
Bid2.1100 x 200
Ask2.1500 x 100
Day's range2.1100 - 2.2000
52-week range1.3300 - 4.2980
Volume111,237
Avg. volume367,935
Market cap80.869M
Beta (5Y monthly)2.78
PE ratio (TTM)N/A
EPS (TTM)-3.0900
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.42
  • GlobeNewswire

    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

    Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercializationBOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 ye

  • GlobeNewswire

    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

    Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s diseaseBOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s di

  • GlobeNewswire

    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

    Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosisBOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster pre